Chemotherapy-Induced Nausea and Vomiting: Strategies for Achieving Optimal Control
|
|
- Imogen Stewart
- 6 years ago
- Views:
Transcription
1 Chemotherapy-Induced Nausea and Vomiting Strategies for Achieving Learning Objectives Describe the challenges of assessing nausea in patients undergoing chemotherapy and the impact of nausea and also vomiting on patient health and QoL Review evidence-based data and guidelines on the management of delayed CINV Develop well-designed communication strategies to ensure that patients are armed with adequate knowledge regarding their prescribed therapy, including potential adverse events CINV = chemotherapy-induced nausea and vomiting; QoL = quality of life. Burden of CINV Debilitating AEs from cytotoxic chemotherapy; can lead to: Dehydration, electrolyte imbalance Anorexia Hospitalization Impaired QoL Patient concern over CINV can affect adherence to antineoplastic medicines Controlling CINV is an important component of maintaining patients QoL during cancer treatment AE = adverse event. Salsman JM, et al. J Natl Compr Canc Netw. 2012;10: ; Grunberg SM. J Support Oncol. 2004;2(1 Suppl 1):1-10. PCE Oncology
2 Clinical Impact of CINVINV Potential for treatment interruption or discontinuation Negative implications for QoL, ADLs 1 Physiologic manifestations 1-3 Malnutrition Anorexia Weight loss Dehydration Esophageal tears Patients With No Impa act on Daily Life (%) Multicenter Study Reporting No Impact on Daily Life for Nausea and Vomiting Domains on Day 6 Post Chemotherapy 2 (N = 298) All Patients (n = 144/271 nausea, n = 196/267 vomiting) Nausea Vomiting HEC Patients (n = 20/55 nausea, n = 32/53 vomiting) MEC Patients (n = 124/216 nausea, n = 164/214 vomiting) ADLs = activities of daily living; MEC = moderately emetogenic chemotherapy. 1. Wiser W, et al. Oncology. 2005;19: ; 2. Bloechl-Daum B, et al. J Clin Oncol. 2006;24: ; 3. Navari RM. Community Oncol. 2007;4(Suppl 1):3-11. Financial Impact of CINV Patient 1 : Increases direct costs Medication Office visits Hospitalizations ti Emergency room visits Increases indirect costs Missed work Caregiver 1 : Missed work to care for patient/family member Total Estimated Direct Medical Costs per Patient per Month 2 $12,000 $10,000 $8,000 $6,000 $4,000 $2,000 $0 $10,720 Uncontrolled CINV $8,923 Controlled CINV Uncontrolled CINV defined as having 1 office visit, emergency room visit, or hospitalization with ICD-9 diagnosis of nausea/vomiting or dehydration. 1. Broder MS, et al. Am Health Drug Benefits. 2014;7: ; 2. Shih YCT, et al. Cancer. 2007;110: CINV Remains a Significant Challenge % of Patients With CINV Despite Antiemetic Therapy CINV (%) 70% 60% 50% 51% 62% Therapy consistent with guidelines Therapy inconsistent with guidelines 46% 48% Patients Experiencing 40% 30% 20% 10% 0% HEC MEC Data from a prospective observational study enrolling chemotherapy-naïve patients who received single-day HEC or MEC at 4 oncology practice networks, all using electronic medical record systems, in Georgia, Tennessee, and Florida. CINV defined as emesis or clinically significant nausea on days 1-5. HEC = 5-HT 3 + NK 1 + CS on day 1; NK 1 on days 2-3; CS on days 2-4. MEC = 5-HT 3 + NK 1 + CS on day 1; 5-HT 3, NK 1, or CS on days 2-3. CS = corticosteroid; 5-HT 3 = 5-hydroxytryptamine-3 (serotonin); NK 1 = neurokinin-1. Gilmore JW, et al. J Oncol Pract. 2014;10: PCE Oncology
3 Case Study: Amanda 33-year-old woman with a new diagnosis of breast cancer Social history: Smoker, drinks socially, exercises regularly Medical history: Hypothyroidism, anxiety, gastroesophageal reflux disease, nausea during pregnancy First cycle of chemotherapy: Cyclophosphamide 600 mg/m 2 IV, doxorubicin 60 mg/m 2 IV on day 1 (pegfilgrastim support) Repeated every 14 days for 4 cycles IV = intravenous. CINV: Risk Factors Risk of CINV increases with the number of risk factors Patient-Related Treatment-Related Previous episodes of CINV Chemotherapy regimen Age <50 years Chemotherapy dose Female sex Route, rate of administration Pregnancy-induced Emetogenicity of treatment nausea/vomiting regimen History of motion sickness History of limited alcohol intake Grunberg SM. J Support Oncol. 2004;2(Suppl 1):1-10; Feinberg BA, et al. Community Oncol. 2010;7: CINV: Additional Risk Factors Physiologic Brain metastases Electrolyte disturbances Gastroparesis Gastritis Concurrent medications Bowel obstruction Vestibular dysfunction Behavioral Lack of guideline adherence Patient expectation of nausea Prechemotherapy anxiety PCE Oncology
4 Patient Perceptions of the Most Severe Side Effects of Cancer Chemotherapy Rank Vomiting Nausea Nausea Nausea Fatigue 2 Nausea Chronic fatigue Hair loss Hair loss Nausea 3 Hair loss Hair loss Vomiting 4 5 Thought of coming for treatment Length of treatment time Effect on family Vomiting Chronic fatigue Injections Chronic fatigue Vomiting Changes in how things taste Sleep disturbances Weight loss Hair loss Coates A, et al. Eur J Cancer Clin Oncol. 1983;19:203-8; Griffin AM, et al. Ann Oncol. 1996;7: ; De Boer-Dennert M, et al. Br J Cancer. 1997;76: ;Lindley C, et al. Cancer Pract. 1999;7: Case Study: Sid 65-year-old man with lung cancer Social history: Former smoker; nondrinker Medical history: Myocardial infarction 2 years ago; being treated for hypertension and dyslipidemia Scheduled for second cycle of chemotherapy, but had nausea/vomiting several days after initiation of first cycle Chemotherapy regimen: carboplatin, pemetrexed, bevacizumab IV on day 1 Every 21 days for 4-6 cycles Definitions of CINV Acute: onset within minutes to hours of administration of chemotherapy Resolves in 24 hours Delayed: occurs 24 hours after administration of chemotherapy Typically resolves in 3 days Occurs in 50%-90% of patients receiving HEC and in 35%-70% of those treated with MEC in absence of prophylaxis Breakthrough/refractory: occurs despite appropriate prophylaxis; requires rescue medication, sometimes repeatedly Anticipatory: occurs before subsequent chemotherapy cycles Associated with poor control of CINV in a previous cycle PCE Oncology
5 Conceptual Model of Acute and Delayed CINV 5-HT 3 sensitive phase Prokinetic-sensitive phase Emesis 5-HT NK 1 -sensitive phase Intensity of Steroid-sensitive phase Disrupted gut motility Cell breakdown products Time (Days) Adapted from Andrews PL, Davis CJ. In: Andrews PL, Sanger GJ. Emesis in Anti-cancer Therapy: Mechanisms and Treatment. Chapman and Hall Medical; 1993: Neurotransmitters in Emesis Dopamine (D2) Histamine Cannabinoids Endorphins Emetic Reflex Serotonin (5-HT 3 ) Acetylcholine Substance P (NK 1 ) γ-aminobutyric acid Slide courtesy of Paul Hesketh, MD. Signaling Pathways Involved in CINV Brainstem Vomiting Center Area postrema Chemoreceptor trigger zone Nucleus tractus solitarius Dorsal motor nucleus of the vagus nerve Substance P/NK 1 receptors a Serotonin/5-HT 3 receptors GI Vagal Afferent Nerve Fibers Serotonin/5-HT 3 receptors Substance P/NK 1 receptors a Studies suggest NK 1 RAs in the brain are the primary site of anti-cinv activity for NK 1 RAs. RA = receptor antagonist. Aziz F. Ann Palliat Med. 2012;1: PCE Oncology
6 Key Principles of Antiemetic Therapy Goal No emesis or nausea Administration i ti Treatment choice Other considerations Administer prophylactically Combine agents with differing mechanisms Match antiemetic to emetogenic potential of chemotherapy Multidrug regimen: base on most emetogenic agent Schedule antiemetics for duration of risk of CINV Individualize regimens Prior experience with antiemetics Patient risk factors Lowest fully effective antiemetic dose(s) before chemotherapy PO vs IV antiemetics: convenience to patients, clinicians Choice based on cost, patient preference Drug-drug interactions of current NK 1 RAs Potential for serotonin syndrome Complications of repeated corticosteroid dosing PO = oral. Emetogenic Potential of Single Antineoplastic Agents High >90% of patients at risk Moderate 30%-90% of patients at risk Low 10%-30% of patients at risk Minimal <10% of patients at risk NCCN Clinical Practice Guidelines in Oncology. Antiemesis Version Emetogenic Potential of IV Antineoplastic Agents Level Agent HEC MEC AC combination, defined as doxorubicin or epirubicin with cyclophosphamide Carboplatin AUC 4 Carmustine >250 mg/m 2 Aldesleukin >12-15 million IU/m 2 Amifostine >300 mg/m 2 Arsenic trioxide Azacitidine Bendamustine Busulfan Carboplatin AUC <4 a Carmustine a 250 mg/m 2 Cisplatin Cyclophosphamide >1500 mg/m 2 Dacarbazine Doxorubicin 60 mg/m 2 Clofarabine Cyclophosphamide 1500 mg/m 2 Cytarabine >200 mg/m 2 Dactinomycin a Daunorubicin a Dinutuximab Doxorubicin a <60 mg/m 2 Epirubicin a 90 mg/m 2 Idarubicin Epirubicin >90 mg/m 2 Ifosfamide 2 g/m 2 per dose Mechlorethamine Streptozocin Ifosfamide a <2 g/m 2 per dose Interferon alfa 10 million IU/m 2 Irinotecan a Melphalan Methotrexate a 250 mg/m 2 Oxaliplatin a Temozolomide Trabectedin a a May be highly emetogenic in some patients. AC = anthracycline + cyclophosphamide. NCCN Practice Guidelines in Oncology. Antiemesis Version PCE Oncology
7 Emetogenic Potential of Oral Antineoplastic Agents Level High or moderate Low or minimal Altretamine Busulfan ( 4 mg/d) Ceritinib Crizotinib Cyclophosphamide ( 100 mg/m 2 /d) Estramustine Etoposide Lenvatinib Agent Lomustine (single day) Mitotane Olaparib Panobinostat Procarbazine Rucaparib Temozolomide (>75 mg/m 2 /d) Trifluridine/tipiracil Afatinib Dabrafenib Melphalan Temozolomide Alectinib Erlotinib Mercaptopurine ( 75 mg/m 2 /d) Axitinib Everolimus Methotrexate Thalidomide Bexarotene Fludarabine Nilotinib Thioguanine Bosutinib Gefitinib Osimertinib Topotecan Busulfan (<4 mg/d) Hydroxyurea Pazopanib Trametinib Cabozantinib Ibrutinib Pomalidomide Tretinoin Capecitabine Idelalisib Ponatinib Vandetanib Chlorambucil Imatinib Regorafenib Vemurafenib Cobimetinib Ixazomib Ruxolitinib Venetoclax Cyclophosphamide Lapatinib Sonidegib Vismodegib (<100 mg/m 2 /d) Lenalidomide Sorafenib Vorinostat Dasatinib Sunitinib NCCN Clinical Practice Guidelines in Oncology. Antiemesis Version Pharmacologic Agents for CINV Serotonin receptor antagonists (5-HT 3 RAs) Neurokinin-1 receptor antagonists (NK 1 RAs) 5-HT 3 RA/NK 1 RA combination Olanzapine Corticosteroids Evolution of Antiemetics for CINV 1980s 1990s High-dose Approval of Approval of metoclopramide first-generation second-generation 5-HT 3 RAs 5-HT (ondansetron 3 RA (palonosetron) and granisetron) Approval of first oral NK 1 RA (aprepitant) Approval of IV NK 1 RA (fosaprepitant) Approval of oral lfixed-dose dd combination (palonosetron + netupitant) Approval of oral NK 1 RA (rolapitant) PCE Oncology
8 Considerations in Agent Selection: Comparison of 5-HT 3 RAs Agent Dolasetron Granisetron Ondansetron Palonosetron Recommended Dose 100 mg PO 1 mg (max) IV or 2 mg PO; 34.3 mg patch; 10 mg SC ER 8-16 mg IV or mg PO 0.25 mg IV (0.5 mg PO) Equivalent safety/efficacy at equivalent doses; can be used interchangeably Single dose preferred Palonosetron Longer half-life (40 hours) than other agents in class Greater 5-HT 3 receptor binding affinity ASCO = American Society of Clinical Oncology; ER = extended release; SC = subcutaneous. 1. NCCN Clinical Practice Guidelines in Oncology. Antiemesis Version ; 2. Basch E, et al. J Clin Oncol. 2011:29: ; 3. De Leon A. Proc (Bayl Univ Med Cent). 2006;19: Pharmacokinetic and Physiologic Differences Among 5-HT 3 RAs 5-HT 3 RA Half-life, Hours Binding Affinity, pki Dolasetron ~7.0 ~7.6 Granisetron ~9.0 (ER ~24) ~8.9 Ondansetron ~4.0 ~8.4 Palonosetron ~40.0 ~10.5 pki = concentration. Aapro M, et al. Springer Science & Business Media. Nov 12, 2013 ; Sustol [prescribing information]. Heron Therapeutics; HT 3 RAs: Treatment-Related Adverse Reactions Adverse Reaction Palonosetron mg IV (n = 187) Ondansetron 1 32 mg IV (n = 187) Granisetron 2 1 mg PO 2/day (n = 978) Headache, n (%) 9 (4.8) 10 (5.3) 205 (21) Constipation, n (%) 3(16) (1.6) 3(16) (1.6) 176 (18) Dizziness, n (%) 1 (0.5) 6 (3.2) NR Postdose change from baseline in QTc 1 ms 5 ms Adverse reactions judged by the investigator to have a definite, probable, possible, or unknown relationship to study medication; reported in 2% of patients in any treatment group NR = not reported as a major adverse event. 1. Gralla R, et al. Ann Oncol. 2003;14: ; 2. Kytril [prescribing information]. Roche; PCE Oncology
9 Are Short--acting 5-HT 3 Antiemetics Effective for Delayed CINV? 671 patients on doxorubicin-based chemotherapy All treated with first-generation 5-HT 3 RA + dexamethasone, day 1 Then randomized for days 2, 3: Arm 1: prochlorperazine 10 mg PO every 8 hours Arm 2: any oral 5-HT 3 RA, standard dosing regimens Arm 3: prochlorperazine 10 mg PO prn for nausea Rescue medications allowed Patients Wit th Delayed Nause ea, % Most Patients Had Nausea Prochlorperazine Every 8 Hours* 83 5-HT 3 87 Prochlorperazine prn *P =.002 (overall comparison); P =.06, prochlorperazine every 8 hours vs 5-HT 3 RA; P = NS, prochlorperazine as needed vs 5-HT 3 RA. NS = not significant. Hickock JT, et al. Lancet Oncol. 2005;6: Oral 5HT 3 RAs Not Effective and Not Indicated for Delayed CINV Vomiting More patients vomited 1 times during delayed period (34%) than on day of treatment (34% vs 9%, P <.01) Nausea Nausea severity greater during delayed period than on day of treatment (P <.01) More patients taking oral 5HT 3 RAs required rescue medication (45%) than did those taking prochlorperazine (27%-30%; P =.002) Hickock JT, et al. Lancet Oncol. 2005;6: MAGIC Trial: Granisetron SC Versus Ondansetron Complete Response, Delayed CINV CR (%) 100 Granisetron SC Ondansetron P = Delayed Delayed-phase CR rate: higher with granisetron SC vs ondansetron (64.7% vs 56.6%; P =.014) Overall population: CR rates: 8.0% higher with granisetron SC vs ondansetron (95% CI, ; 14 4; P =.014) (relative 14.2% improvement) Cisplatin stratum: CR rates: 10.6% higher with granisetron SC vs ondansetron (95% CI, -1.4 to 22.7; NS) (relative 19.4% improvement) Granisetron SC showed superiority vs another 5-HT 3 RA in HEC in a guidelineconsistent 3-drug vs 3-drug study design CR = complete response. Schnadig ID, et al. Future Oncol. 2016;12: PCE Oncology
10 Chemotherapy-Induced Nausea and Vomiting: Strategies for Achieving Current Status of NK 1 RAs in CINV FDA-approved agents Aprepitant: 125 mg PO day 1; 80 mg PO days 2 and 3 Fosaprepitant: 150 mg IV day 1 NEPA (netupitant 300 mg + palonosetron 0.5 mg) Rolapitant Good safety profile; significantly enhanced CINV control when combined with 5-HT 3 RA + dexamethasone More effective in emesis vs nausea control Consensus guideline-recommended use Single-day HEC (including AC) Other potential uses MEC Multiday HEC; high-dose chemotherapy with ASCT ASCT = autologous stem cell transplant; FDA = US Food and Drug Administration. NK 1 RAs Aprepitant 1 Netupitant 2-4 Rolapitant 5,6 Formulation PO, IV (fosaprepitant) Fixed-dose PO formulation with palonosetron (NEPA) Indication Dose CYP3A4 activity Prevention of acute and delayed Prevention of acute and nausea/vomiting associated with delayed nausea/vomiting initial/repeat courses of HEC associated with initial/repeat courses of chemotherapy 125 mg PO 1 hour before chemotherapy; 80 mg PO once daily in morning, days 2 and mg netupitant mg palonosetron ~1 hour before chemotherapy Can affect metabolism of Moderate inhibitor of CYP3A4, concomitantly administered although no clinically relevant medications (eg, corticosteroids, interaction with PO PO contraceptives, warfarin) contraceptives observed metabolized through this route PO and IV Prevention of acute and delayed nausea/vomiting associated with initial/repeat courses of chemotherapy 200 mg PO Does not affect metabolism of concomitantly administered medications metabolized by CYP3A4 1. Emend [prescribing information]. Merck; 2017; 2. Calcagnile S, et al. Support Care Cancer. 2013;21: ; 3. Stathis T, et al. Eur J Pharmacol. 2012;689:25-30; 4. Spinelli T, et al. J Clin Pharmacol. 2014;54:97-108; 5. Duffy RA, et al. Pharm Biochem Behav. 2012;102:95-100; 6. Poma A, et al. Support Care Cancer. 2013;21:S154. Abstract 441. NEPA Phase 3 Trial in AC Chemotherapy: CR Rates Patients (% %) P = P = P = Acute (0 24 h) Delayed ( h) Overall (0 120 h) NEPA + DEX PALO + DEX DEX = dexamethasone; PALO = palonosetron. CR: no emesis, no rescue medication. Based on full analysis set of 1449 patients. Aapro M, et al. Ann Oncol. 2014;25: PCE Oncology
11 CR With Rolapitant and NEPA in Phase 3 MEC Studies P =.143 CR Rate P <.001 P < % 68.6% 61.6% 57.8% 80.3% 83.5% Delayed Phase Overall Phase Acute Phase (> h) (0-120 h) (0-24 h) Active Control (N = 666) Rolapitant 200 mg (N = 666) CR Rate P =.001 P =.001 P = % 88.4% 76.9% 74.3% 69.5% 66.6% Delayed Phase Overall Phase Acute Phase (> h) (0-120 h) (0-24 h) PALO (N = 725) NEPA (N = 724) Schwartzberg L, et al. Lancet Oncol. 2015;16: ; Aapro M, et al. Ann Oncol. 2014;25: Olanzapine Olanzapine (atypical antipsychotic) Mechanism of action in CINV: unknown Possible neurotransmitter receptors blocked include dopaminergic, serotonergic, catecholamine α 1 adrenergic, acetylcholine muscarinic, histamine Use with caution in elderly Prophylaxis for acute/delayed CINV Alternative to aprepitant Also effective for breakthrough CINV Navari RM, et al. J Support Oncol. 2013;21: Olanzapine Versus Aprepitant for Prevention of CINV in Patients Receiving HEC Acute Delayed Overall CR (No Emesis, No Rescue), % OPD (n = 121) APD (n = 120) No Nausea, % OPD (n = 121) APD (n = 120) APD = aprepitant + palonosetron, dexamethasone; OPD = olanzapine + palonosetron + dexamethasone. Navari RM, et al. J Support Oncol. 2011;9: PCE Oncology
12 Addition of Olanzapine to CINV Regimen in Patients Receiving HEC All patients received dexamethasone, NK 1 RA, 5-HT 3 RA 74% * 45% No Nausea (%) 42% 25% 37% Olanzapine Placebo 22% 86% * 65% 67% CR (%) Olanzapine Placebo 52% 64% * 41% Time After Chemotherapy (Hours) *P <.001; P =.001; P =.002; P =.007. Navari RM, et al. N Engl J Med. 2016;375: Corticosteroids Uncertain mechanism of action May involve prostaglandin synthesis inhibition in hypothalamus Effective as single agent or in combination therapy Potentiate effects of other antiemetics Effective for acute and delayed CINV de Jong FA, et al. J Clin Oncol. 2005;23: ; Hesketh PJ. N Engl J Med. 2008;358: ; Jantunen IT, et al. Eur J Cancer. 1997;33:66-74; Perwitasari DA, et al. Int J Clin Pharm. 2011;33: Effect of Adding Dexamethasone to 5-HT 3 RAs for Acute Emesis Number of Patients Vomiting/Number of Patients Evaluable Author Hesketh Smith Roila Joss Smyth Heron Latreille Italian group Carmichael Sorbe Adams Total 0 5-HT 3 + Dexamethasone Better Treatment effect P < HT 3 2 Better Jantunen IT, et al. Eur J Cancer. 1997;33: PCE Oncology
13 Clinical Guidelines for Prevention of CINV Group Last Updated HEC NCCN HT 3 RA + DEX + NK 1 RA Olanzapine + PALO + DEX ASCO HT 3 RA + DEX + NK 1 RA MASCC/ HT 3 RA + DEX + ESMO 3 NK 1 RA Recommendation MEC 5-HT 3 RA (PALO, GRAN SQ preferred) + DEX ± NK 1 Olanzapine + PALO + DEX 5-HT 3 RA (PALO preferred) + DEX Palonosetron + DEX GRAN SQ = granisetron subcutaneous. 1. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version ASCO 2015 Antiemetics Focused Update; 3. MASCC/ESMO Antiemetic Guideline Update. Ann Oncol. 2016;27(Suppl 5):v119-v133. HEC: Guideline Recommendations NCCN 1 ASCO 2 Acute CINV 5-HT 3 RA + NK 1 RA + DEX PALO + olanzapine + DEX NK 1 RA + 5HT 3 RA + DEX + olanzapine 5-HT 3 RA + NK 1 RA + DEX NEPA + DEX Delayed CINV (Days 2-3) DEX + APR a Olanzapine DEX + APR a MASCC b3 5-HT 3 + DEX + APR DEX + APR a Delayed CINV (Day 4) DEX Olanzapine DEX a If fosaprepitant used, day 1 only; b AC. APR = aprepitant. 1. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version ASCO 2015 Antiemetics Focused Update; 3. MASCC/ESMO Antiemetic Guideline Update. Ann Oncol. 2016;27(Suppl 5):v119-v133. MEC: Guideline Recommendations Acute CINV Delayed CINV (Days 2-3) NCCN 1 5 HT 3 RA (PALO preferred) + DEX +/- NK 1 RA a,b Olanzapine + PALO + DEX 5-HT 3 (if PALO not used day 1) DEX APR +/- DEX a Olanzapine c ASCO 2 PALO + DEX b DEX MASCC d3 PALO + DEX d DEX a If fosaprepitant used, day 1 only; b If APR added, PALO not preferred; c If used on day 1; d Non-AC. 1. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version ASCO 2015 Antiemetics Focused Update; 3. MASCC/ESMO Antiemetic Guideline Update. Ann Oncol. 2016;27(Suppl 5):v119-v133. PCE Oncology
14 Case Study: Amanda Amanda receives an antiemetic regimen consisting of palonosetron + dexamethasone + fosaprepitant on day 1, dexamethasone once daily on day 2, and dexamethasone twice daily on days 3 and 4 However, after 2 days, she experiences nausea and vomiting that severely weaken her Before the next cycle of therapy, she is given a 4-drug regimen as recommended in the 2017 NCCN guidelines Addition of Olanzapine to CINV Regimen in Patients Receiving HEC All patients received dexamethasone, NK 1 RA, 5-HT 3 RA No Nausea (%) CR (%) 74% * 86% * 45% 42% 25% 37% Olanzapine Placebo 22% 65% 67% 52% Olanzapine Placebo 64% * 41% Time After Chemotherapy (Hours) *P <.001; P =.001; P =.002; P =.007. Navari RM, et al. N Engl J Med. 2016;375: Principles for Managing Breakthrough CINV Add agent from a different class Consider around-the-clock rather than as-needed administration If patient is vomiting, IV or rectal administration may be required Before next cycle of chemotherapy, reassess response in both acute and delayed setting Consider an alternative regimen if needed Add an NK 1 RA if not previously included NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version PCE Oncology
15 Radiation-Induced Nausea and Vomiting: Prophylaxis and Treatment For patients treated with highly or moderately emetogenic radiation therapy, a 5-HT 3 RA before each fraction; a 5-day course of dexamethasone 4 mg is recommended/optional Breakthrough treatment: same as for CINV NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version ; ASCO 2015 Antiemetics Focused Update. Much Progress Has Been Made But Challenges Remain Prevention of nausea remains a challenge Many patients consider CINV a necessary evil Adherence to guidelines is poor, due to: Lack of knowledge by healthcare providers Differing recommendations Cost/financial/insurance issues Lack of institutional enforcement Inadequate measurement of quality of care and outcomes Grunberg SM. J Natl Compr Cancer Netw. 2009;7: Improving Adherence Through Education Communicating with and educating patients about CINV is a critical component of oncology patient care Patients need to be aware of the differences between prophylaxis and treatment of symptoms Important to educate patient about how and why to take medication as instructed even if they do not have symptoms Symptom monitoring Use of patient diaries, proactive follow-up calls Give clear communication/contact information Patients should understand that if they have symptoms, they should contact someone regardless of the time Young A, et al. Ecancermedicalscience. 2013;7:296. PCE Oncology
16 PCE Action Plan Consider the burden of CINV, including clinical and financial impact, on patients and caregivers Evaluate risk factors for CINV in patients with cancer Recognize that the goal of antiemetic therapy is prevention, not treatment, of CINV Evaluate the antiemetic potential of anticancer regimens Consider multiple strategies to manage breakthrough CINV Develop strategies to prevent radiation-induced nausea and vomiting Educate patients about the potential for CINV and the importance of prevention with an antiemetic regimen PCE Promotes Practice Change PCE Oncology
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationANTIEMETIC GUIDELINES: MASCC/ESMO
Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:
More informationUpdate on antiemetics, what is new and future directions. Karin Jordan University of Halle
Update on antiemetics, what is new and future directions Karin Jordan University of Halle History of Antiemetics Controlling Chemotherapy-Induced EMESIS: Progress Over The Past 30 Years: Efficacy 5-Day
More informationClinical Tools and Resources for Self-Study and Patient Education
Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationDescription The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationSubject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )
09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationANTIEMETICS UTILIZATION MANAGEMENT CRITERIA
ANTIEMETICS [Akynzeo, Anzemet, Cesamet, Emend, Sancuso, Varubi, Zuplenz ] DRUG CLASS: UTILIZATION MANAGEMENT CRITERIA 5-HT 3 Receptor Antagonists 5-HT 3 Receptor Antagonist and Substance P/Neurokinin (NK
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationChemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care
Chemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care Presented as a Live Webinar Wednesday, April 13, 2016 12:00 p.m. 1:00 p.m. ET Tuesday,
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium Goals and Objectives: Describe
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium 1 Goals and Objectives: Describe
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationChemotherapy Induced Nausea and Vomiting
Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting
More informationNorthern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationSupportive care session 1:
Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Zofran, Zuplenz) Reference Number: CP.CPA.173 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More information9/21/2016. Disclosures. Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Introduction. Objectives.
Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Diwura Owolabi, Pharm.D, BCOP Clinical Pharmacy Specialist, Blood and Marrow Transplantation Methodist University Hospital,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationRichard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY
Oncology Consultations Improving the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) A CE-Certified Activity Featuring Consultations With Supported by an educational grant from Eisai. Dannemiller
More informationSCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
More informationConflicts of Interest. Review of Antiemetic Guidelines. Learning Objectives. What is Emesis Anyways? Pharmacy Technician Learning Objectives
Conflicts of Interest No financial relationships to disclose Review of Antiemetic Guidelines Matthew Fox, PharmD, BCPS, BCOP Clinical Oncology Pharmacist Baptist MD Anderson Jacksonville, Florida October
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Antiemetic Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 8 References... 8 Effective Date... 1/1/2018
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2015 NCCN.org Continue Version 1.2015, 04/01/15 National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN
More informationESMO HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE
ESMO 2016 - HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE FLORIAN SCOTTE Cancer Department Supportive Care in Cancer Unit Georges Pompidou European Hospital Paris France esmo.org DISCLOSURE SLIDE Consultant
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationReview Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 595894, 6 pages http://dx.doi.org/10.1155/2015/595894 Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2016 NCCN.org Continue Version 1.2016 03/15/16 National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The NCCN
More informationDrug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc.
Drug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc. Pharmacology: Aprepitant (previously known as MK-0839 and L-754030) is a new molecular entity that is the first in a new therapeutic class,
More informationOverview of the neurokinin-1 receptor antagonists
Editorial Page 1 of 6 Overview of the neurokinin-1 receptor antagonists Rudolph M. avari Division of Hematology Oncology, School of Medicine, University of Alabama Birmingham, Birmingham, AL, USA Correspondence
More informationSystemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kytril, Sancuso, Sustol) Reference Number: CP.PMN.74 Effective Date: 11.01.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important
More informationANTIEMETIC RESEARCH AND PROGRESS: Richard J. Gralla, MD, FACP Professor of Medicine Albert Einstein College of Medicine Bronx, New York
ANTIEMETIC RESEARCH AND PROGRESS: Richard J. Gralla, MD, FACP Professor of Medicine Albert Einstein College of Medicine Bronx, New York THE FUTURE OF ANTIEMETICS Fausto Roila Medical Oncology, Terni, Italy
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationMASCC/ESMO ANTIEMETIC GUIDELINE 2016
1 MASCC/ESMO ANTIEMETIC GUIDELINE 2016 Multinational Association of Supportive Care in Cancer Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex
More informationManagement of chemotherapyinduced nausea and vomiting
p h a r m a c o t h e r a p y Management of induced nausea and vomiting Authors Key words F. Van Ryckeghem and S. Van Belle Antiemetic therapy,, prevention Summary Chemotherapy-induced nausea and vomiting
More informationRolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting Tamara Goldberg, PharmD, BCPS; Brooke Fidler, PharmD; and Stephanie Cardinale,
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue
Table of Contents Clinical in Oncology Version 2.2010 Continue www.nccn.org Version 2.2010, 04/07/2010 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration
More informationDelayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
Support Care Cancer (2011) 19 (Suppl 1):S57 S62 DOI 10.1007/s00520-010-1039-y SPECIAL ARTICLE Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) Fausto Roila & David
More informationCHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to the edit Experts Master
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationDefining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice
Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice PAUL J. HESKETH St. Elizabeth s Medical Center, Boston, Massachusetts, USA Key Words. Chemotherapy Emesis Emetogenicity
More informationPREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK
PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK HISTORY OF ANTIEMETICS 1979 A corticosteroid is superior
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationClinical Review Report
CADTH COMMON DRUG REVIEW Clinical Review Report Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue Pharma) Indication: In combination with dexamethasone, onceper-cycle treatment for the prevention
More informationMedicare Part C Medical Coverage Policy
Medicare Part C Medical Coverage Policy Oral Antiemetic Medications Origination: June 17, 2009 Review Date: May 17, 2017 Next Review: May, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Oral antiemetic medications
More informationGuideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version March 28, 2017 NCCN.org
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2017 March 28, 2017 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue Version2.2017 03/28/17 National
More informationSafe Practices in Oral Anticancer Medications: Implications for Community Pharmacy
Safe Practices in Oral Anticancer Medications: Implications for Community Pharmacy Faculty Disclosures Dr. Holle has provided content expertise on patient education materials for Innocrin Pharmaceuticals
More informationInternational Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany. What was hot at MASCC/ISOO Annual Meeting this year?
International Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany What was hot at MASCC/ISOO Annual Meeting this year? Supportive Care Makes Excellent Cancer Care Possible. This slogan
More informationSURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO. PARTECIPATE TUTTI nicsonet.it
SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO PARTECIPATE TUTTI www.cipomo.it; nicsonet.it LINEE GUIDA AIOM: LA TERAPIA ANTIEMETICA Fausto Roila S.C. Oncologia Medica, Terni
More informationChemotherapy-induced nausea and vomiting (CINV)
At a Glance Practical Implications e54 Author Information e57 Full text and PDF 5-HT3 Receptor Antagonist Effects in Cancer Patients With Multiple Risk Factors Original Research Claudio Faria, PharmD,
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationAvailable online at ScienceDirect. journal homepage:
European Journal of Cancer 57 (2016) 23e30 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.ejcancer.com Original Research Efficacy and safety of rolapitant for prevention
More informationCompany Update. September 2016
Company Update September 2016 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationReview Article Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 309601, 7 pages http://dx.doi.org/10.1155/2015/309601 Review Article Prevention of Nausea and Vomiting in Patients Undergoing
More informationDavid G. Frame, PharmD. he etiology of nausea and vomiting is multifactorial,
r e v i e w Best Practice Management of CINV in Oncology Patients: I. Physiology and Treatment of CINV Multiple Neurotransmitters and Receptors and the Need for Combination Therapeutic Approaches David
More informationOriginal. Key words : breast cancer, chemotherapy-induced nausea and vomiting, quality of life, Functional Living Index Emesis
Showa Univ J Med Sci 30 2, 285 296, June 2018 Original The Impact on Quality of Life of Highly Effective Antiemetic Therapy among Breast Cancer Patients Receiving Anthracycline Plus Cyclophosphamide-based
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationAn Evidence Practice Gap in Antiemetic Prescription with Chemotherapy
2014 An Evidence Practice Gap in Antiemetic Prescription with Chemotherapy Chepsy C Philip 1*, Biju George 1 1 Department of Clinical Haematology, CMC Vellore, Tamil Nadu, India. ARTICLE INFO Article type:
More informationPediatric Trials 23/04/2018. Disclosures. Nausea and Vomiting Control in Adults and Children: Mind the Gap! Learning Objectives
Nausea and Vomiting Control in Adults and Children: Mind the Gap! Disclosures No relevant conflicts of interest Lee Dupuis, RPh, PhD May 5, 2018 2 Learning Objectives At the end of this presentation, attendees
More informationTrust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults
A Clinical Guideline For Use in: Organisation-wide By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager:
More informationChemotherapy induced emesis: Are we doing are best? David Warr University of Toronto
Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto david.warr@uhn.on.ca Conflict of interest Merck: speakers bureau and consultant Eisai: consultant Outline What is the
More informationDrug: Aprepitant (Emend ) Date of Review: 4/01/10
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Business Case Evaluation and Recommendation Document Drug: Aprepitant (Emend ) Date of Review: 4/01/10 Business Case Decision and date: DOUBLE RED, 20 January 2010
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Antiemesis. Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2011 NCCN.org Continue Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that
More informationMOLECULAR AND CLINICAL ONCOLOGY 2: , 2014
MOLECULAR AND CLINICAL ONCOLOGY 2: 375-379, 2014 Palonosetron exhibits higher total control rate compared to first generation serotonin antagonists and improves appetite in delayed phase chemotherapy induced
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationPatient-Centered Management of Chemotherapy-Induced Nausea and Vomiting
Clear and accurate communication between patients and health care teams is the key to successfully controlling chemotherapy-induced nausea and vomiting. Roseate Spoonbill_2005. Photograph courtesy of Henry
More informationclinical practice guidelines
clinical practice guidelines Annals of Oncology 21 (Supplement 5): v232 v243, 2010 doi:10.1093/annonc/mdq194 Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced
More informationPERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER
June 2004 PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY PERUGIA, March 29-31, 2004 DELAYED EMESIS WORKING
More informationPrevention of chemotherapy induced nausea and vomiting in pediatric cancer patients
REVIEW ARTICLE Prevention of chemotherapy induced nausea and vomiting in pediatric cancer patients Shubham Roy 1, Rashi Kulshrestha 2, Abhishek Shankar 3, Goura Kishor Rath 4, Vipin Kharade 4 1 Department
More informationGuidelines for Assessment and Management of Nausea and Vomiting
Guidelines for Assessment and Management of Nausea and Vomiting To Prevent and Manage Nausea and Vomiting Induced by Chemotherapy Or Related to Other Oncologic Etiologies Dana Farber Cancer Institute Brigham
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationComparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens
569 Ivyspring International Publisher Research Paper Journal of Cancer 2016; 7(5): 569-575. doi: 10.7150/jca.13637 Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk
More information